A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer

Rohit Chugh, Veena Sangwan, Satish P. Patil, Vikas Dudeja, Rajinder Dawra, Sulagna Banerjee, Robert J. Schumacher, Bruce R. Blazar, Gunda I. Georg, Selwyn M. Vickers, Ashok Saluja

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Pancreatic cancer is one of the most lethal human malignancies with an all-stage 5-year survival frequency of <5%, which highlights the urgent need for more effective therapeutic strategies. We have previously shown that triptolide, a diterpenoid, is effective against pancreatic cancer cells in vitro as well as in vivo. However, triptolide is poorly soluble in water, limiting its clinical use. We therefore synthesized a water-soluble analog of triptolide, named Minnelide. The efficacy of Minnelide was tested both in vitro and in multiple independent yet complementary in vivo models of pancreatic cancer: an orthotopic model of pancreatic cancer using human pancreatic cancer cell lines in athymic nude mice, a xenograft model where human pancreatic tumors were transplanted into severe combined immunodeficient mice, and a spontaneous pancreatic cancer mouse model (KRasG12D; Trp53R172H; Pdx-1Cre). In these multiple complementary models of pancreatic cancer, Minnelide was highly effective in reducing pancreatic tumor growth and spread, and improving survival. Together, our results suggest that Minnelide shows promise as a potent chemotherapeutic agent against pancreatic cancer, and support the evaluation of Minnelide in clinical trials against this deadly disease.

Original languageEnglish (US)
Article number156ra139
JournalScience Translational Medicine
Volume4
Issue number156
DOIs
StatePublished - Oct 17 2012
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Therapeutics
Nude Mice
Neoplasms
SCID Mice
Survival
14-O-phosphonooxymethyltriptolide
Water
Diterpenes
Heterografts
Clinical Trials
Cell Line
Growth
triptolide

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer. / Chugh, Rohit; Sangwan, Veena; Patil, Satish P.; Dudeja, Vikas; Dawra, Rajinder; Banerjee, Sulagna; Schumacher, Robert J.; Blazar, Bruce R.; Georg, Gunda I.; Vickers, Selwyn M.; Saluja, Ashok.

In: Science Translational Medicine, Vol. 4, No. 156, 156ra139, 17.10.2012.

Research output: Contribution to journalArticle

Chugh, Rohit ; Sangwan, Veena ; Patil, Satish P. ; Dudeja, Vikas ; Dawra, Rajinder ; Banerjee, Sulagna ; Schumacher, Robert J. ; Blazar, Bruce R. ; Georg, Gunda I. ; Vickers, Selwyn M. ; Saluja, Ashok. / A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer. In: Science Translational Medicine. 2012 ; Vol. 4, No. 156.
@article{cbb4a7cb4f994c1b82f03d6e9be3552f,
title = "A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer",
abstract = "Pancreatic cancer is one of the most lethal human malignancies with an all-stage 5-year survival frequency of <5{\%}, which highlights the urgent need for more effective therapeutic strategies. We have previously shown that triptolide, a diterpenoid, is effective against pancreatic cancer cells in vitro as well as in vivo. However, triptolide is poorly soluble in water, limiting its clinical use. We therefore synthesized a water-soluble analog of triptolide, named Minnelide. The efficacy of Minnelide was tested both in vitro and in multiple independent yet complementary in vivo models of pancreatic cancer: an orthotopic model of pancreatic cancer using human pancreatic cancer cell lines in athymic nude mice, a xenograft model where human pancreatic tumors were transplanted into severe combined immunodeficient mice, and a spontaneous pancreatic cancer mouse model (KRasG12D; Trp53R172H; Pdx-1Cre). In these multiple complementary models of pancreatic cancer, Minnelide was highly effective in reducing pancreatic tumor growth and spread, and improving survival. Together, our results suggest that Minnelide shows promise as a potent chemotherapeutic agent against pancreatic cancer, and support the evaluation of Minnelide in clinical trials against this deadly disease.",
author = "Rohit Chugh and Veena Sangwan and Patil, {Satish P.} and Vikas Dudeja and Rajinder Dawra and Sulagna Banerjee and Schumacher, {Robert J.} and Blazar, {Bruce R.} and Georg, {Gunda I.} and Vickers, {Selwyn M.} and Ashok Saluja",
year = "2012",
month = "10",
day = "17",
doi = "10.1126/scitranslmed.3004334",
language = "English (US)",
volume = "4",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "156",

}

TY - JOUR

T1 - A preclinical evaluation of minnelide as a therapeutic agent against pancreatic cancer

AU - Chugh, Rohit

AU - Sangwan, Veena

AU - Patil, Satish P.

AU - Dudeja, Vikas

AU - Dawra, Rajinder

AU - Banerjee, Sulagna

AU - Schumacher, Robert J.

AU - Blazar, Bruce R.

AU - Georg, Gunda I.

AU - Vickers, Selwyn M.

AU - Saluja, Ashok

PY - 2012/10/17

Y1 - 2012/10/17

N2 - Pancreatic cancer is one of the most lethal human malignancies with an all-stage 5-year survival frequency of <5%, which highlights the urgent need for more effective therapeutic strategies. We have previously shown that triptolide, a diterpenoid, is effective against pancreatic cancer cells in vitro as well as in vivo. However, triptolide is poorly soluble in water, limiting its clinical use. We therefore synthesized a water-soluble analog of triptolide, named Minnelide. The efficacy of Minnelide was tested both in vitro and in multiple independent yet complementary in vivo models of pancreatic cancer: an orthotopic model of pancreatic cancer using human pancreatic cancer cell lines in athymic nude mice, a xenograft model where human pancreatic tumors were transplanted into severe combined immunodeficient mice, and a spontaneous pancreatic cancer mouse model (KRasG12D; Trp53R172H; Pdx-1Cre). In these multiple complementary models of pancreatic cancer, Minnelide was highly effective in reducing pancreatic tumor growth and spread, and improving survival. Together, our results suggest that Minnelide shows promise as a potent chemotherapeutic agent against pancreatic cancer, and support the evaluation of Minnelide in clinical trials against this deadly disease.

AB - Pancreatic cancer is one of the most lethal human malignancies with an all-stage 5-year survival frequency of <5%, which highlights the urgent need for more effective therapeutic strategies. We have previously shown that triptolide, a diterpenoid, is effective against pancreatic cancer cells in vitro as well as in vivo. However, triptolide is poorly soluble in water, limiting its clinical use. We therefore synthesized a water-soluble analog of triptolide, named Minnelide. The efficacy of Minnelide was tested both in vitro and in multiple independent yet complementary in vivo models of pancreatic cancer: an orthotopic model of pancreatic cancer using human pancreatic cancer cell lines in athymic nude mice, a xenograft model where human pancreatic tumors were transplanted into severe combined immunodeficient mice, and a spontaneous pancreatic cancer mouse model (KRasG12D; Trp53R172H; Pdx-1Cre). In these multiple complementary models of pancreatic cancer, Minnelide was highly effective in reducing pancreatic tumor growth and spread, and improving survival. Together, our results suggest that Minnelide shows promise as a potent chemotherapeutic agent against pancreatic cancer, and support the evaluation of Minnelide in clinical trials against this deadly disease.

UR - http://www.scopus.com/inward/record.url?scp=84867793735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867793735&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3004334

DO - 10.1126/scitranslmed.3004334

M3 - Article

C2 - 23076356

AN - SCOPUS:84867793735

VL - 4

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 156

M1 - 156ra139

ER -